Trending...
- KDM Engineering Wins the 2022 Business Diversity Award from the Edison Electric Institute
- Andrew Eshelman Joins Board of Directors of Paxton Patterson
- Do You Have Any Experience With Play-To-Earn Games/NFTs?
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 10, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced the Company will release the progress of the next-generation anti-CTLA-4 antibody HBM4003 studies of monotherapy and combination therapy with anti-PD-1 antibody at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on June 3-7 in Chicago.
Details for the presentations:
Abstract One
Title: A Phase I Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects with Advanced Solid Tumors
Abstract number: 363712
Publication Format: Poster
Abstract Two:
Title: A Phase I Open-label Study to Evaluate the Safety, Tolerability, PK/PD and Anti-tumor Activity of HBM4003 in Combination with Toripalimab in Subjects with Advanced Melanoma and Other Solid Tumors
Abstract number: 368316
Publication Format: Abstract
"We are extremely pleased to announce the progress of HBM4003 studies at ASCO Annual Meeting 2022. HBM4003 has a remarkable safety and tolerability profile with encouraging anti-tumor efficacy. Given the high therapeutic promise of HBM4003, we are proceeding with multiple global phase Ib/IIa trials in solid tumors. We look forward to bringing this novel therapeutic to cancer patients worldwide." Said Dr. Humphrey Gardner, CMO of Harbour BioMed.
More on illi News
HBM4003 has demonstrated strong efficacy and excellent safety profile. It is believed that this product will have the potential to lead the development of next generation therapy of immuno-oncology, especially combination therapeutics. The Company will continue to be fully committed to advancing the global clinical development project of HBM4003, furthering its global innovation and development strategy in 2022.
Harbour BioMed is developing HBM4003 as part of its broad and innovative immuno-oncology pipeline to address significant unmet medical needs in many solid tumor indications.
About HBM4003
HBM4003 is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice®. It is the first fully human heavy-chain-only monoclonal antibody entered into clinical stage globally. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, HBM4003 has demonstrated significantly improved depletion specific to high CTLA-4 expressing Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combination therapy.
More on illi News
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.
The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, HBICE® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.
SOURCE Harbour BioMed
Details for the presentations:
Abstract One
Title: A Phase I Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects with Advanced Solid Tumors
Abstract number: 363712
Publication Format: Poster
Abstract Two:
Title: A Phase I Open-label Study to Evaluate the Safety, Tolerability, PK/PD and Anti-tumor Activity of HBM4003 in Combination with Toripalimab in Subjects with Advanced Melanoma and Other Solid Tumors
Abstract number: 368316
Publication Format: Abstract
"We are extremely pleased to announce the progress of HBM4003 studies at ASCO Annual Meeting 2022. HBM4003 has a remarkable safety and tolerability profile with encouraging anti-tumor efficacy. Given the high therapeutic promise of HBM4003, we are proceeding with multiple global phase Ib/IIa trials in solid tumors. We look forward to bringing this novel therapeutic to cancer patients worldwide." Said Dr. Humphrey Gardner, CMO of Harbour BioMed.
More on illi News
- Latino Leaders Network to Honor Mayor Tim Keller of Albuquerque with Antonio Villaraigosa Leadership Award at the 36th Tribute to Mayors
- Chamberlain University Receives Major Grant from American Nurses Foundation for Practice-Ready, Specialty-Focused™ Program
- Meet the owner of the tech company disrupting an $11.0bn industry
- Procurement Partners Welcomes Troy Thibodeau as Chief Marketing Officer
- Net Diatom diversifies with corporate restructure
HBM4003 has demonstrated strong efficacy and excellent safety profile. It is believed that this product will have the potential to lead the development of next generation therapy of immuno-oncology, especially combination therapeutics. The Company will continue to be fully committed to advancing the global clinical development project of HBM4003, furthering its global innovation and development strategy in 2022.
Harbour BioMed is developing HBM4003 as part of its broad and innovative immuno-oncology pipeline to address significant unmet medical needs in many solid tumor indications.
About HBM4003
HBM4003 is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice®. It is the first fully human heavy-chain-only monoclonal antibody entered into clinical stage globally. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, HBM4003 has demonstrated significantly improved depletion specific to high CTLA-4 expressing Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combination therapy.
More on illi News
- Chicago Resilient Communities Pilot Receives Over 176,000 Applications; Participant Selection Starts This Month
- Industrial and systems engineers honored at international conference
- Sims Tillirson VP, Business Development at PERKS appears on The Zemar Podcast
- Heather Morgan Joins Hilco Corporate Finance as Director of Capital Solutions
- Chicago: New 'Corridor Ambassador' Program to Support 13 Neighborhood Shopping Areas
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.
The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, HBICE® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.
SOURCE Harbour BioMed
Filed Under: Business
0 Comments
Latest on illi News
- Inventhelp Inventor Develops a Specialty Device Used to Prevent the Spread of Illness (CHK-147)
- Howie Mandel Joins NOCD to Change the OCD Conversation
- Average American Spends $78 On Jewelry Annually, Finds New CWC Jewelry Market Study
- OBL Crowns Chicago Regional Champion at Hope Academy Athletic Center and Awards $10,000 First Prize
- CARS.COM REPORTS 82% OF HOLIDAY TRAVELERS WILL ROAD-TRIP THIS MEMORIAL DAY, WITH MORE THAN HALF CARPOOLING TO SAVE ON GAS
- Hyfé Foods Turns Wasted Sugar Water into Flour Amidst a Supply Chain Crunch
- Midea Showcases FlashChef™ and Scan&Go™ Series for Professional Kitchens at the National Restaurant Association Show 2022
- Do You Have Any Experience With Play-To-Earn Games/NFTs?
- ForeFront Power Installs 2.4 MW of Solar at Eight of Anheuser-Busch's Partner Craft Breweries Across the Country
- Chicago: Statement from Mayor Lori E. Lightfoot
- 750 Prebuilt Assessments Now Available in Otus
- Chicago: Mayor Lightfoot and Alderman Ramirez-Rosa Join Bickerdike Redevelopment Corporation for the Grand Opening of Emmett Street Apartments
- Welcome AWATFIT The Fitness Truck to Fort Lauderdale
- Brazilian Plant-Based Food Innovator Future Farm To Participate in National Restaurant Association Show
- Walgreens Honors Veterans, Active Duty Military and Their Families with Weekend Discount in Honor of Memorial Day Friday, May 27 through Monday, May 30
- Cornerstone and Swiftlane Announce Strategic Technology Initiative to Create Safer Rental Communities in Denver
- KDM Engineering Wins the 2022 Business Diversity Award from the Edison Electric Institute
- Atkore Inc. Announces Acquisition of Talon Products, LLC
- TOKYO SKYTREE Celebrates Its 10th anniversary! Let's Pay Homage to this Japanese Landmark and World's Tallest Freestanding Broadcast Tower
- Andrew Eshelman Joins Board of Directors of Paxton Patterson